Lexicon Pharmaceuticals (LXRX) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LXRX Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Lexicon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.59 |
| 52 Week High | US$1.83 |
| 52 Week Low | US$0.36 |
| Beta | 0.95 |
| 1 Month Change | -7.02% |
| 3 Month Change | 39.47% |
| 1 Year Change | 279.57% |
| 3 Year Change | -32.91% |
| 5 Year Change | -70.39% |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
Jan 22Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up
Jan 22
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Dec 18Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%
Oct 02There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump
Jul 28Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
Jun 13Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
May 19Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates
May 17
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Mar 28Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%
Mar 26Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Shareholder Returns
| LXRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.6% | 3.8% | 3.5% |
| 1Y | 279.6% | 37.2% | 31.0% |
Return vs Industry: LXRX exceeded the US Pharmaceuticals industry which returned 37.2% over the past year.
Return vs Market: LXRX exceeded the US Market which returned 31% over the past year.
Price Volatility
| LXRX volatility | |
|---|---|
| LXRX Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: LXRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LXRX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 81 | Mike Exton | www.lexpharma.com |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.
Lexicon Pharmaceuticals, Inc. Fundamentals Summary
| LXRX fundamental statistics | |
|---|---|
| Market cap | US$673.65m |
| Earnings (TTM) | -US$50.34m |
| Revenue (TTM) | US$49.80m |
Is LXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXRX income statement (TTM) | |
|---|---|
| Revenue | US$49.80m |
| Cost of Revenue | US$6.56m |
| Gross Profit | US$43.24m |
| Other Expenses | US$93.58m |
| Earnings | -US$50.34m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 86.82% |
| Net Profit Margin | -101.08% |
| Debt/Equity Ratio | 50.2% |
How did LXRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/05 16:48 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lexicon Pharmaceuticals, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Andrew Tsai | Jefferies LLC |